Correlation between the development of extracolonic manifestations in FAP patients and mutations beyond codon 1403 in the APC gene

Zuzana Dobbie, Martina Spycher, Jean-Luc Mary, Michèle Häner, Irene Guldenschuh, Reiner Hirliman, Rudolf Amman, Jürgen Roth, Hansjakob Müller, Rodney J Scott

Abstract

The APC gene was investigated in 31 unrelated polyposis coli families by SSCP analysis and the protein truncation test. Twenty-three germline mutations were identified which gave rise to a variety of different phenotypes. Some of these mutations have already been described; however we report six previously unpublished mutations. Typical disease symptoms were observed in families who harboured mutations between exon 4 (codon 169) and codon 1393 of exon 15. Mutations beyond codon 1403 were associated with more varied phenotype with respect to the development of extracolonic symptoms. In this report we provide support for the notion that there appears to be a correlation between the location of an APC mutation (beyond codon 1403) and extracolonic manifestations of familial adenomatous polyposis.

(J Med Genet 1996;33:274-280)

Key words: polyposis coli; mutation; protein truncation test.

Familial adenomatous polyposis is probably the best defined colorectal cancer syndrome. It is an autosomal dominantly inherited disease characterised by hundreds to thousands of adenomatous polyps in the colon and rectum with a prevalence of approximately 1 in 10,000. The probability that colorectal cancer will develop in untreated FAP patients approaches 100% by 40 years of age.

Germline mutations in the adenomatous polyposis coli (APC) gene appear to be the initiating event for the development of this disorder. This gene was localised to 5q21-22 and subsequently cloned.1-4 It consists of 15 exons, the first 14 of which are relatively short, whereas exon 15 spans over 6.5 kb. The gene encodes a protein of 2843 amino acids. The protein has been shown to form homodimers, such that the first 171 residues are sufficient and the first 45 amino acids necessary for this interaction.5

Two groups6,7 isolated APC protein in association with catenins, a family of intracellular polypeptides which interact with E-cadherin to regulate cell-cell communication. Consequently a catenin binding domain was localised to a triple repeated 15 amino acid consensus sequence in the central region of the protein (between codons 1014 and 1210). Additionally, the APC protein contains multiple binding and regulatory sites for β-catenin containing a 20 amino acid consensus sequence between amino acids 1342-2075. By down-regulation or redistribution of β-catenin, the APC protein has an important effect on catenin levels within the cell.8-12 Finally, two recent studies13,14 examined the subcellular localisation of the APC protein and showed that the wild type APC protein colocalised with cytoplasmic microtubules whereas mutant APC protein did not. The carboxy-terminal region of the APC protein appears to be essential for this association. Thus, the function of the APC protein could be in signal transmission from catenins to the cytoskeleton and, in turn, from the inside of the cell via catenins to the extracellular matrix.14

There is clinical variability in genetically confirmed FAP patients. The APC phenotype is usually determined using two parameters, the number and age of onset of colorectal polyps and the presence or absence of extracolonic manifestations. Variant forms of FAP have been described and are known as either the attenuated form of APC (AAPC)15 or the flat adenoma syndrome.16 These are characterised by a smaller number of polyps, later age of onset, and slower evolution of disease. In the reported kindreds, AAPC appears to arise from mutations occurring at the amino-terminus of the APC gene.17,18 In contrast, other manifestations in addition to colonic polyps may occur, which include polyps of the upper gastrointestinal tract, desmoids, osteomas, fibromas, and lipomas. These symptoms are the hallmarks of the more severe form of the disease (commonly referred to as Gardner’s syndrome).

Several different techniques have been used in the analysis of the APC gene, such as single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), or the ribonuclease (RNase) protection assay. The observation that the majority of mutations in the APC gene result in a truncated protein (>95%) allowed the development of a test based on an examination of the APC gene product.19,20 The recently developed protein truncation test (PTT) relies on the identification of an artificially created truncated protein using an in vitro transcription and translation assay of genomic PCR products.
In this report we have used both SSCP and PTT to determine germline mutations in the entire coding region of the APC gene within a set of 31 polyposis coli families. We have correlated these mutations with the phenotypic severity of the disease with respect to the development of extracolonic lesions. Our results indicate that there appears to be a relationship between the site of mutation and the likelihood of more severe disease.

Subjects and methods

FAP FAMILIES

The group of 31 unrelated polyposis coli families were examined for mutations in exon 15. This included five families (two AAPC and three typical) with previously detected mutations in exons 1–14 to ensure that no other causative mutation was present. The 26 families which did not harbour any mutation in exons 1–14 presented with a variety of different disease phenotypes (table 1). Eighteen families were characterised as having typical FAP with multiple colorectal polyps observed by colonoscopy or after colectomy. In eight families, patients developed additional extracolonic symptoms including osteomas (five families), detected during regular dental examination, desmoids (four families), diagnosed by computed tomography, lipomas (three families), fibromas (three families), diagnosed by careful medical examination, and upper gastrointestinal polyps (five families), mainly in the stomach observed by endoscopy. For the purposes of this report we classified these eight families as having a severe form of the disease.

In total there were four new polyposis cases with no previous family history of colorectal or upper gastrointestinal tract cancer. The selection of these cases was based on an early age of onset and the presence of multiple polyps throughout the entire colon. All these patients presented with symptoms typical of polyposis coli.

The age at which index patients were diagnosed varied from 13 to 64 years with a mean of 35·3 years.

PROTEIN TRUNCATION TEST

The in vitro synthesised protein assay was performed as described by Powell et al.44 Exon 15 of the APC gene was divided into four overlapping segments (segment 2, 3, 4, 5), as shown in fig 1, containing codons 686 to 1217, 1099 to 1693, 1555 to 2256, and 2131 to 2843. The primers for amplification were designed to introduce a T7 promoter sequence for the initiation of transcription by T7 RNA polymerase, as well as a consensus sequence for initiation of translation. For the 50 μl PCR reaction, 200 ng of genomic DNA was used, as well as 50 pmol of each primer, 500 pmol of each dNTP, 1 mmol/l (for segment 4) or 2 mmol/l (for segments 2, 3, 5) MgCl₂, 2 U T7aq polymerase, and 1 × reaction buffer (10 mmol/l Tris, 50 mmol/l KCl, 0·2 mg/ml BSA, pH 8·5). The reaction parameters were 30 seconds at 94°C, 90 seconds at 60°C (for segment 2), 62°C (for segment 3), 58°C (for segment 4), and 60°C (for segment 5), and 90 seconds at 70°C for 35 cycles.

PCR products were used directly as templates in 25 μl coupled transcription-translation reaction (Promega, Madison, WI, USA) using 30 μCi of S⁻³⁵-methionine (Dupont, Boston, MA). Samples were incubated for 70 minutes at 30°C, diluted in sample buffer, heated for 5 minutes at 95°C, and analysed on 12% SDS/polyacrylamide gel. The gels were impregnated with ENHANCE (Dupont, Boston, MA) and the proteins were visualised by autoradiography.

PCR-SSCP ANALYSIS

The polymerase chain reaction (PCR) was used to amplify genomic DNA obtained from peripheral blood lymphocytes.45 Primer sets used to amplify exon 15 of the APC gene were as previously described. Briefly, 10 μl PCR

<table>
<thead>
<tr>
<th>Family No</th>
<th>FH/NF</th>
<th>Mutation</th>
<th>Codon</th>
<th>NT change</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1506</td>
<td>FH</td>
<td>3/-</td>
<td>99</td>
<td>cga-tga</td>
<td>Mild</td>
</tr>
<tr>
<td>1464</td>
<td>FH</td>
<td>4/-</td>
<td>151</td>
<td>del c</td>
<td>Mild</td>
</tr>
<tr>
<td>11</td>
<td>FH</td>
<td>4/-</td>
<td>169-170</td>
<td>del (atg)</td>
<td></td>
</tr>
<tr>
<td>197</td>
<td>NF</td>
<td>6/-</td>
<td>232</td>
<td>cga-tga</td>
<td></td>
</tr>
<tr>
<td>1528</td>
<td>NF</td>
<td>11/-</td>
<td>498</td>
<td>del a</td>
<td></td>
</tr>
<tr>
<td>1382</td>
<td>FH</td>
<td>-/b</td>
<td>793</td>
<td>del a</td>
<td></td>
</tr>
<tr>
<td>215</td>
<td>FH</td>
<td>-/f</td>
<td>805</td>
<td>cga-tga</td>
<td></td>
</tr>
<tr>
<td>1468</td>
<td>FH</td>
<td>-/c</td>
<td>935</td>
<td>tac-taa</td>
<td></td>
</tr>
<tr>
<td>1471</td>
<td>FH</td>
<td>-/e</td>
<td>1061</td>
<td>del (aca)</td>
<td></td>
</tr>
<tr>
<td>1478</td>
<td>FH</td>
<td>-/e</td>
<td>1061</td>
<td>del (aca)</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>NF</td>
<td>-/e</td>
<td>1062</td>
<td>del (aca)</td>
<td></td>
</tr>
<tr>
<td>1557</td>
<td>FH</td>
<td>-/e</td>
<td>1135</td>
<td>del (c)</td>
<td></td>
</tr>
<tr>
<td>1519</td>
<td>FH</td>
<td>-/f</td>
<td>1193</td>
<td>del (ca)</td>
<td></td>
</tr>
<tr>
<td>114</td>
<td>FH</td>
<td>-/g</td>
<td>1324</td>
<td>del c</td>
<td></td>
</tr>
<tr>
<td>246</td>
<td>NF</td>
<td>-/g</td>
<td>1324</td>
<td>del c</td>
<td></td>
</tr>
<tr>
<td>1539</td>
<td>FH</td>
<td>-/h</td>
<td>1373</td>
<td>del (ac)</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>FH</td>
<td>-/h</td>
<td>1393</td>
<td>tca-tga</td>
<td></td>
</tr>
<tr>
<td>177</td>
<td>FH</td>
<td>-/h</td>
<td>1403</td>
<td>del c</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>FH</td>
<td>-/h</td>
<td>1450</td>
<td>cga-tga</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>FH</td>
<td>-/h</td>
<td>1465</td>
<td>del (ag)</td>
<td></td>
</tr>
<tr>
<td>1469</td>
<td>FH</td>
<td>-/i</td>
<td>1987</td>
<td>del a</td>
<td></td>
</tr>
<tr>
<td>1488</td>
<td>FH</td>
<td>-/i</td>
<td>1987</td>
<td>del a</td>
<td></td>
</tr>
<tr>
<td>1501</td>
<td>FH</td>
<td>-/i</td>
<td>1987</td>
<td>del a</td>
<td></td>
</tr>
</tbody>
</table>

FH = family history of colorectal cancer, NF = non-familial case.
RPN = range of poly number: A, under 100, B, 100–1000, C, over 1000.
D = desmoid, L = lipoma, F = fibroma, O = osteoma, SIP = small intestinal polyps, SP = stomach polyps.
reaction mixture contained 200 ng genomic DNA, 0.5 μmol/l each primer, 2.5 μmol/l each dNTP, 5 mmol/l MgCl₂, 0.2 U Taq polymerase, 1× reaction buffer (10 mmol/l Tris, 50 mmol/l KCl, 0.2 mg/ml BSA, pH 8.5), and 0.1 μl of 3000 Ci (α-32P) dCTP/mmol (Dupont, Boston,
### Results

Using both PTT and SSCP analysis, the entire coding region of exon 15 of the APC gene was examined for the presence of germline mutations in 31 unrelated polyposis coli families. If samples from family members were available, new bands were tested for cosegregation with the disease phenotype. New conformers were sequenced to determine the precise site and type of mutation.

The five families in whom we previously reported a mutation\(^1\) in exons 1–14 did not show any additional anomaly within the APC gene.

Using the PTT, 12 truncating mutations were detected in the remaining 26 FAP patients. Six families harboured a causative mutation in segment 2 (fig 1A) and DNA sequencing showed alterations in codons 935, 1061 (two families), 1062, 1135, and 1193. In three families a protein truncation was detected in segment 3 (fig 1B) involving codons 1403, 1450, and 1465. A further three families showed an additional protein band in segment 4 (fig 1C) which corresponded to a 1 bp deletion in codon 1987. This mutation appears to be unique to the Swiss population.\(^2\)

In six additional families, APC mutations in codons 793, 805, 1324 (two families), 1373, and 1393 were identified only by SSCP and confirmed by sequence analysis.

Codons 1961 and 1465 were considered to be APC mutational hot spots and in the current study we observed three families harbouring the mutations in either one of these two codons. Interestingly, no mutation was observed in the most frequently described site at codon 1390. As far as we can ascertain, mutations in codons 805, 1135, 1324, 1373, 1393, and 1403 have not been previously published.

In total, germline mutations in exon 15 were observed in 18 polyposis coli families representing 58·1% of our collection. The summary of these mutations (and mutations determined within the same set of families in exons 1–14 as described previously\(^1\)) are listed in table 1 with their corresponding phenotypes. Altogether, disease causing APC mutations were identified in 23 of 31 screened FAP families, representing 74·2%. The remaining eight families did not appear to harbour any APC gene mutation.

There was no correlation observed between the number of polyps in the patients and the location of the APC mutation in exon 15.

Interestingly, in our data set, patients from families harbouring mutations 5’ of codon 1393 presented with typical FAP but no extracolonic disease to date. Mutations in segments 3 and 4 (in codons 1403–1478), however, cosegregated with a more complicated phenotype. Twenty-one subjects from six families were identified who had germline mutations within this region of the APC gene (table 2). Eleven of these people developed various extracolonic lesions. Eight of them have not presented so far with

---

**Figure 2. Functional domains in the APC gene and related phenotypes of our FAP patients.** Detected mutations (arrows) are shown below. Asterisks indicate the mutations reported previously.
any extracolonic symptom; however, they are all younger than 25 years of age. Two patients were unavailable for further investigation.

Discussion

The in vitro synthetic protein (IVSP) assay or the protein truncation test (PTT) is a recently described method for the identification of protein truncating mutations in the APC gene. This is by virtue of the fact that 97% of all APC mutations reported to date result in premature stop codons.

There are, however, problems with the sensitivity of the technique, as in our hands 33% of our confirmed truncating mutations in exon 15 were not detected using PTT. One explanation that accounts for the failure to detect mutations occurring close to the 5' end of the segments is the small size of the mutated protein product, which may not be as efficiently translated as the expected wild type product. Alternatively, or in addition, the resolving capacity of the acrylamide gel may not be sufficient to detect small protein products as even on a 10−20% gradient gel these predicted synthetic peptides were not observed.

As all mutations detected by PTT were confirmed by SSCP it was possible to calculate the relative percentage of mutations detected using the two methods. From the 18 confirmed mutations in exon 15, 66% were detected by PTT and 94% by SSCP. Therefore, we conclude that SSCP is more sensitive than PTT. As, however, the PTT is rapid and simple we can recommend its application, at least in the first phase of APC mutation screening.

Even though two detection methods were used to establish the presence of APC germline mutations, eight FAP families did not appear to harbour mutations in the coding region of the APC gene. Several explanations could account for this finding. Owing to there being splice site variation in the APC gene, an intron/exon splice acceptor or donor mutation may give rise to an aberrant misspliced variant, which may not be identified by some of the oligonucleotides used in this study. In addition, mutations occurring in promoter or enhancer regions may also account for the failure to detect mutations.

Several reports have been published attempting to correlate the clinical variability of FAP with a particular location of mutations in the APC gene.

The presence of germline mutations in the very 5' region of the APC gene appears to correlate with a smaller number of polyps and slower disease progression. These mutations give rise to very short proteins, which are probably unable to dimerise with wild type monomers and therefore do not act in a dominant negative manner. Spirio et al. suggested a functional boundary within the APC gene (codons 157–168) that determines the phenotypic characteristics of typical FAP and AAPC families. Interestingly, probably not all mild cases of polyposis coli are related to this APC region as some could arise as a result of any mutation within the gene which presumably does not significantly alter APC function.

A profuse number of colorectal polyps appeared to be associated with mutations located between codons 1250–1464 of the APC gene. Several authors found that families with mutations in codon 1309 and 3' of it tend to have a more severe disease phenotype with an earlier onset of colonic disease and extracolonic symptoms. Very recently, Caspari et al. showed that patients with mutations between codons 1445–1578 generally tend to develop osteomas, epidermoid cysts, upper gastrointestinal polyps, and desmoid tumours. Scott et al. observed a large family with a unique mutation in the APC gene (codon 1987) presenting with a variety of phenotypes including variable polyposis number and frequently extracolonic disease.

Several groups, however, did not observe any correlation between the mutation site and extracolonic manifestations of FAP and presumed that these were not associated with the type or location of the mutation. The majority of these studies, however, did not report mutations beyond codon 1403 as these are relatively rare.
Correlation between the development of extracolonic manifestations in FAP patients and mutations beyond codon 1403 in the APC gene

Mutations from exon 4 to codon 1393 in exon 15 resulted in a typical FAP phenotype in our data set, but this is probably not significant as several reports have been published indicating that mutations occurring in this region can also result in a severe phenotype.\(^\text{26,31,32}\)

Interestingly, all six families (11 patients) harbouring mutations downstream and including codon 1403 were clinically associated with the more severe form of the disease. Only mutation carriers of exon 15 who were younger than 25 years of age were free of extracolonic symptoms. This appears to be significant, as to our knowledge there has been no report indicating that typical disease without additional extracolonic lesions is associated with a mutation located beyond codon 1403.

So far there is no evidence to explain why these mutations lead to the expression of an unpredictable and often severe disease phenotype. One proposal could be that truncations beyond codon 1403 give rise to a protein that is incapable of associating with microtubules, but is able to bind to catenin (fig 2), thus effecting the physiological role of catenin. Alternatively, a more severe disease phenotype could be a result of a lack of β-catenin down-regulating activity even though catenin binding activity is still present.

Disease expression could alternatively be the result of a modifying gene that may either suppress or enhance disease characteristics. In favour of this explanation are experiments with the Min mouse (multiple intestinal neoplasia) which harbours an ApC mutation (mutine homologue of ApC).\(^\text{33-36}\) The results of these studies indicate the presence of a modifying gene,\(^\text{37}\) which affects, at least, tumour multiplicity.

Very recently, a candidate gene was reported, namely, secretory type II phospholipase A\(_2\.\)\(^\text{38}\) Additionally, the presence of other modifying loci appears to be the most likely explanation. Some mutations may, however, be so dominant that modifier genes may not strongly influence disease expression. Therefore similar phenotypes between different persons carrying the same mutation may still be observed, as appears to be the case for mutations at codon 1309.\(^\text{39}\)

In conclusion, we report the identification of 22 APC exon I mutations in a set of 31 polyposis coli patients. To perform this mutational screening we applied both SSCP analysis and the recently described PTT. We believe that the PTT is a rapid and reliable alternative as an initial screen compared to other methods. SSCP analysis, although more tedious, appears to be a more reliable method of mutation detection. We observed an apparent correlation between the location of APC mutations beyond codon 1403 and extracolonic disease in polyposis coli patients.


32. Groden J, Gelbert L, Thliveris A, et al. Mutational analysis of patients with adenomatous polyposis: identical in-


Correlation between the development of extracolonic manifestations in FAP patients and mutations beyond codon 1403 in the APC gene.

Z Dobbies, M Spycher, J L Mary, M Häner, I Guldenschuh, R Hürliman, R Amman, J Roth, H Müller and R J Scott

doi: 10.1136/jmg.33.4.274